Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
- Seven abstracts highlighting ALGS and PFIC data, including three oral presentations
- Long-term extension data from Phase 3 MARCH-ON PFIC study presented at plenary session and selected among the.
FOSTER CITY - Mirum Pharmaceuticals, Inc. today announced that the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee has recommended public reimbursement for.
- Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with this rare liver disorder
- LIVMARLI is the first and only.